Novartis

Novartis
Share
Novartis Oncology discovers and develops innovative therapies that help change the way patients live with cancer and blood disorders, including Gleevec® (imatinib mesylate), Tasigna® (nilotinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole tablets), Sandostatin® LAR Depot (octreotide acetate for injectable suspension), and Exjade® (deferasirox). Novartis Oncology has one of the broadest and most comprehensive pipelines in the industry.

Novartis

 •  June 23

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data
Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months
Advances in CTL019 and ELIANA result from...

Novartis

 •  June 7

At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achieving CR; full results expected to be available later in 2017 and will serve as basis for US and EU regulatory submissions Global, multi-center Phase...

Novartis

 •  June 6

Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab)
Collaboration expands upon existing clinical investigation of Opdivo combination with Novartis investigational and marketed therapies Basel, June 5, 2017 - Novartis today announced it has entered into a clinical research...

Novartis

 •  May 22

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing CLL treatments also had a higher overall response rate (84% vs 68%) compared to fludarabine and cyclophosphamide alone Chronic lymphocytic leukemia (CLL) is...

Novartis

 •  April 20

NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy[1]
The historical complete response rate was 10% for untreated patients with SAA on immunosuppressive therapy alone[1]
Findings...

Novartis

 •  April 18

Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation Advances in CTL019 result from...

Novartis

 •  April 3

New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate in both previously treated and untreated patients[1] Approximately 1-3% of patients with lung cancer are diagnosed annually with BRAF V600-positive NSCLC...

Novartis

 •  December 6, 2016

Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1]
Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%[1]
Data will be used to support global regulatory...

Novartis

 •  November 16, 2016

This December, the oncology community will travel across the US and beyond to discuss the latest developments in cancer care at three key medical conferences: the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH) in San Diego, California; the annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas; and...

Novartis

 •  November 7, 2016

On average, it takes 10 years to research and develop a new medicine, such as a new cancer treatment.1 That’s a long time to wait for patients facing a devastating diagnosis like advanced or metastatic cancer for which there is no cure. While clinical research is a careful, scientific process that takes time, on the development side, regulatory...